By targeting the NLRP3-ASC/TMS1-Caspase 3 pathway, Kae appears to mitigate liver damage and inflammation, offering a promising avenue for the treatment of NASH. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.